VINCENT is a randomized-controlled, multicenter, non-inferiority, phase 2 trial (NCT05904106) evaluating VEN/AZA versus SOC in adults aged 18–70 years with newly diagnosed, NPM1-mutated, FLT3-wildtype AML. Here, NPM1 is linked to acute myeloid leukemia.